Shots:
- The EC has approved Breyanzi for r/r follicular lymphoma adults treated with ≥2 previous lines of systemic therapy in 30 EEA states
- Approval was based on global P-II (TRANSCEND FL) study, assessing Breyanzi’s safety & efficacy to treat r/r indolent B-cell NHL incl. FL
- In pts treated in 3L+ setting, study met its 1EP with an ORR of 97.1%, while also achieving its 2EP of 94.2% CR rate. Subsequently, it showed mToR of 0.95mos., with 75.7% pts maintaining response at 18mos.
Ref: BMS | Image: BMS
Related News:- BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
